<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025085</url>
  </required_header>
  <id_info>
    <org_study_id>C-1400-01</org_study_id>
    <nct_id>NCT05025085</nct_id>
  </id_info>
  <brief_title>A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agenus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Agenus Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, Phase 1 study to evaluate the safety, tolerability,&#xD;
      pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in&#xD;
      combination with a PD-1 inhibitor in participants with advanced, metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose-Limiting Toxicities (DLT) of AGEN1777 as a Single-Agent and in Combination with a PD-1 inhibitor</measure>
    <time_frame>Day 1 through Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 2 years and 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration at Steady State (Cmax-ss) of Serum AGEN1777 and a PD-1 inhibitor</measure>
    <time_frame>Day 1 Up to End of Treatment (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum AGEN1777 Anti-Drug Antibody (ADA) Determination</measure>
    <time_frame>Day 1 of Cycle 1 (Cycle = 21 days) through Day 1 of Cycle 5. Incidence of ADA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum a PD-1 inhibitor Anti-Drug Antibody (ADA) Determination</measure>
    <time_frame>Day 1 Up to End of Treatment (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) Based on Investigator's assessment</measure>
    <time_frame>From Day 1 of Cycle 1 (each cycle is 21 days [3 weeks]) until every 9 weeks (±7 days) for 12 months, and every 12 weeks (±7 days) thereafter up to 2 years or until progressive disease or unacceptable toxicity</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response (PR) per RECIST v1.1 Based on Investigator's Assessment</measure>
    <time_frame>From Day 1 of Cycle 1 (each cycle is 21 days [3 weeks]) until every 9 weeks (±7 days) for 12 months, and every 12 weeks (±7 days) thereafter up to 2 years or until progressive disease or unacceptable toxicity</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per RECIST v1.1 Based on Investigator's Assessment</measure>
    <time_frame>From Day 1 of Cycle 1 (each cycle is 21 days [3 weeks]) until every 9 weeks (±7 days) for 12 months, and every 12 weeks (±7 days) thereafter up to 2 years or until progressive disease or unacceptable toxicity.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable Disease (SD) per RECIST v1.1 Based on Investigator's Assessment</measure>
    <time_frame>From Day 1 of Cycle 1 (each cycle is 21 days [3 weeks]) until every 9 weeks (±7 days) for 12 months, and every 12 weeks (±7 days) thereafter up to 2 years or until progressive disease or unacceptable toxicity.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Monotherapy with AGEN1777</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3+3 Dose escalation of AGEN1777 will be administered by Intravenous (IV) infusion every 3 weeks (each cycle is 21 days [3 weeks]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGEN1777 in combination with a PD-1 inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3+3 Dose escalation of AGEN1777 in combination with a PD-1 inhibitor will be administered by IV infusion with specified dose on specified days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGEN1777</intervention_name>
    <description>An immunoglobulin gamma (IgG1) antibody</description>
    <arm_group_label>AGEN1777 in combination with a PD-1 inhibitor</arm_group_label>
    <arm_group_label>Monotherapy with AGEN1777</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>a PD-1 inhibitor</intervention_name>
    <description>Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody</description>
    <arm_group_label>AGEN1777 in combination with a PD-1 inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced&#xD;
             solid tumor for which no acceptable standard therapy available or progressed on or&#xD;
             after standard therapies.&#xD;
&#xD;
          2. Measurable disease on baseline imaging based on Response Evaluation Criteria in Solid&#xD;
             Tumors version 1.1 (RECIST 1.1).&#xD;
&#xD;
          3. Life expectancy of at least 3 months and an Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance status of 0 or 1.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Active infection requiring treatment.&#xD;
&#xD;
          2. Lack of recovery for participants who had major surgical procedure within 4 weeks&#xD;
             prior to first dose of protocol therapy.&#xD;
&#xD;
          3. Clinically significant cardiovascular disease: cerebral vascular accident/stroke or&#xD;
             myocardial infarction within 6 months of enrollment, unstable angina, congestive heart&#xD;
             failure (New York Heart Association class ≥ II), or serious uncontrolled cardiac&#xD;
             arrhythmia requiring medication.&#xD;
&#xD;
          4. Corrected QT interval (QTc) (corrected for heart rate using Fridericia's formula&#xD;
             prolongation) &gt;480 msec at screening except for right bundle branch block.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Agenus Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agenus, Inc. Clinical Trial Information</last_name>
    <phone>781-674-4265</phone>
    <email>clinicaltrialinfo@agenusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Burns</last_name>
      <phone>616-954-5559</phone>
      <email>Julie.burns@startmidwest.com</email>
    </contact>
    <investigator>
      <last_name>Manish R. Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Price</last_name>
      <phone>513-584-7824</phone>
      <email>price2m9@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Trisha Wise-Draper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Stadum</last_name>
      <phone>503-215-3577</phone>
      <email>Anne.Stadum@providence.org</email>
    </contact>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lifespan Cancer Institute</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Schumacher</last_name>
      <phone>401-444-3234</phone>
    </contact>
    <investigator>
      <last_name>Benedito A. Carneiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Crowley Referral Office</last_name>
      <phone>972-566-3000</phone>
      <email>referral@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>James Strauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Thoracic-Head &amp; Neck Med Onc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vaslesa Turner</last_name>
      <phone>713-794-3930</phone>
      <email>vvturner@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Maura Gillison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Dose Escalation</keyword>
  <keyword>Monotherapy</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Undisclosed Target</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

